Refractory Solid Tumor Clinical Trial
Official title:
An Open-Label, Non-Randomized, Single-Center, Investigator-Initiated Trial to Determine the Effectiveness of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression
This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD.
Integrin αvβ3 is highly expressed in some tumor cells and neovascularization, which is an ideal target for diagnosis and treatment of solid tumors. 177Lu-AB-3PRGD2, is a kind of new drug based on independent research and development in China, providing an effective target for the treatment of tumors. All patients underwent whole-body 68Ga-RGD PET/CT for selection and accepted intravenous injection with a fixed dose of 2.96 GBq (80 mCi) of 177Lu-AB-3PRGD2 within one week. Treatment is planned for up to 4 cycles, and the time interval between cycles is 6 weeks. The primary endpoint assessed the preliminary treatment efficacy of 177Lu-AB-3PRGD2 used for radioligand therapy in patients with various advanced tumors. The secondary endpoint evaluates the safety of 177Lu-AB-3PRGD2. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04238819 -
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03443622 -
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01558453 -
Oxaliplatin for Children With Solid Tumors
|
Phase 2 | |
| Terminated |
NCT02164097 -
ODSH + ICE Chemotherapy in Pediatric Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05963386 -
Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors
|
Phase 1 | |
| Completed |
NCT00110357 -
Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors
|
Phase 1 |